Is there a role for remote ischemic conditioning in preventing 5-fluorouracil-induced coronary vasospasm?

Conditioning medicine Pub Date : 2019-10-01
Jun Chong, Andrew Fw Ho, Jonathan Yap, Heerajnarain Bulluck, Derek J Hausenloy
{"title":"Is there a role for remote ischemic conditioning in preventing 5-fluorouracil-induced coronary vasospasm?","authors":"Jun Chong,&nbsp;Andrew Fw Ho,&nbsp;Jonathan Yap,&nbsp;Heerajnarain Bulluck,&nbsp;Derek J Hausenloy","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiac ischemia associated with chemotherapy has been linked to several anti-neoplastic agents and is multifactorial in etiology. Coronary artery vasospasm is one of the most commonly reported effects of cancer therapy that can lead to myocardial ischemia or infarction. The chemotherapy agent 5-fluorouracil (5-FU) or its oral pro-drug capecitabine can result in coronary vascular endothelial dysfunction causing coronary artery spasm, and possibly coronary thrombosis. These drugs have also been shown to be associated with myocardial infarction, malignant ventricular arrhythmias, heart failure, cardiogenic shock, and sudden death. The proposed mechanisms underlying cardiotoxicity induced by 5-FU are vascular endothelial damage followed by thrombus formation, ischemia secondary to coronary artery vasospasm, direct toxicity on myocardium, and thrombogenicity. There remains a pressing need to discover novel and effective therapies that can prevent or ameliorate 5-FU associated cardiotoxicity. To this point, promising overlap has been observed between proposed remote ischemic conditioning (RIC) cardioprotective mechanisms and 5FU-associated cardiotoxic cellular pathways. RIC, in which transient episodes of limb ischemia and reperfusion (induced by inflations and deflations of a pneumatic cuff placed on the upper arm or thigh), confer both cardioprotective and vasculoprotective effects, and may therefore prevent 5-FU coronary artery spasm/cardiotoxicity. In this review, we will be discussing the following potentially therapeutic aspects of RIC in ameliorating 5-FU associated cardiotoxicity: sequential phases of 5-FU cardiotoxicity as possible targets for dual windows of cardioprotection characteristic of RIC; protective effects of RIC on endothelial function and microvasculature in relation to 5-FU induced endothelial dysfunction/microvascular dysfunction; reduction in platelet activation by RIC in the context of 5-FU induced thrombogenicity; and the utility of improvement in mitochondrial function conferred by RIC in 5-FU induced cellular toxicity secondary to mitochondrial dysfunction.</p>","PeriodicalId":72686,"journal":{"name":"Conditioning medicine","volume":" ","pages":"204-212"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055861/pdf/nihms-1560711.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Conditioning medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiac ischemia associated with chemotherapy has been linked to several anti-neoplastic agents and is multifactorial in etiology. Coronary artery vasospasm is one of the most commonly reported effects of cancer therapy that can lead to myocardial ischemia or infarction. The chemotherapy agent 5-fluorouracil (5-FU) or its oral pro-drug capecitabine can result in coronary vascular endothelial dysfunction causing coronary artery spasm, and possibly coronary thrombosis. These drugs have also been shown to be associated with myocardial infarction, malignant ventricular arrhythmias, heart failure, cardiogenic shock, and sudden death. The proposed mechanisms underlying cardiotoxicity induced by 5-FU are vascular endothelial damage followed by thrombus formation, ischemia secondary to coronary artery vasospasm, direct toxicity on myocardium, and thrombogenicity. There remains a pressing need to discover novel and effective therapies that can prevent or ameliorate 5-FU associated cardiotoxicity. To this point, promising overlap has been observed between proposed remote ischemic conditioning (RIC) cardioprotective mechanisms and 5FU-associated cardiotoxic cellular pathways. RIC, in which transient episodes of limb ischemia and reperfusion (induced by inflations and deflations of a pneumatic cuff placed on the upper arm or thigh), confer both cardioprotective and vasculoprotective effects, and may therefore prevent 5-FU coronary artery spasm/cardiotoxicity. In this review, we will be discussing the following potentially therapeutic aspects of RIC in ameliorating 5-FU associated cardiotoxicity: sequential phases of 5-FU cardiotoxicity as possible targets for dual windows of cardioprotection characteristic of RIC; protective effects of RIC on endothelial function and microvasculature in relation to 5-FU induced endothelial dysfunction/microvascular dysfunction; reduction in platelet activation by RIC in the context of 5-FU induced thrombogenicity; and the utility of improvement in mitochondrial function conferred by RIC in 5-FU induced cellular toxicity secondary to mitochondrial dysfunction.

远程缺血调节在预防5-氟尿嘧啶引起的冠状血管痉挛中是否有作用?
与化疗相关的心脏缺血与几种抗肿瘤药物有关,并且在病因上是多因素的。冠状动脉血管痉挛是癌症治疗中最常见的影响之一,可导致心肌缺血或梗死。化疗药物5-氟尿嘧啶(5-FU)或其口服前药卡培他滨可导致冠状血管内皮功能障碍,导致冠状动脉痉挛,并可能导致冠状动脉血栓形成。这些药物也被证明与心肌梗死、恶性室性心律失常、心力衰竭、心源性休克和猝死有关。5-FU诱导心脏毒性的潜在机制是血栓形成后的血管内皮损伤、冠状动脉血管痉挛继发的缺血、对心肌的直接毒性和血栓形成性。仍然迫切需要发现能够预防或改善5-FU相关心脏毒性的新的有效疗法。在这一点上,已经观察到所提出的远程缺血预处理(RIC)心脏保护机制和5FU相关的心脏毒性细胞途径之间有希望的重叠。RIC是指短暂的肢体缺血和再灌注(由上臂或大腿上的气动套的充气和放气引起),具有心脏保护和血管保护作用,因此可以预防5-FU冠状动脉痉挛/心脏毒性。在这篇综述中,我们将讨论RIC在改善5-FU相关心脏毒性方面的以下潜在治疗方面:5-FU心脏毒性的连续阶段是RIC心脏保护特征的双窗口的可能靶点;RIC对内皮功能和微血管的保护作用与5-FU诱导的内皮功能障碍/微血管功能障碍的关系;在5-FU诱导的血栓形成性背景下RIC减少血小板活化;以及RIC在5-FU诱导的继发于线粒体功能障碍的细胞毒性中赋予的线粒体功能改善的效用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信